Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive Therapy for Cetuximab-Induced Rash
NCT01874860Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2013
- Primary completion
- Jul 2018
- Countries
- 1
- Sponsor
- University of Louisville
- Modality
- Orthosteric Ligands
- Conditions
- drug eruption
01
Overview
Phase 2, randomised, open-label trial of doxycycline and Alkindi Sprinkle in drug eruption (2 arms), sponsored by University of Louisville. Primary endpoint: Incidence of Rash at 8 weeks. Started Aug 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Extensive Treatment
Doxycycline + Hydrocortisone + Sunscreen + Moisturizer
Standard Care
Reactive treatment only
03
Who it enrols
Adult patients with colorectal or head and neck cancer scheduled to receive cetuximab, excluding those with prior cetuximab within 6 months or current TKI treatment.
04
Endpoints
Primary
Incidence of Rash
Secondary
Quality of Life
Adherence to treatment regimen
Progression Free Survival
Beyond the preview
Go deeper on NCT01874860.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874860.